25I-NBOMe
| Clinical data | |
|---|---|
| Other names | 2C-I-NBOMe; 25I-NB2OMe; 25I; 25i; N-Bomb; Smiles; Wizard; INBMeO; Cimbi-5; Cimbi-5-2; N-(2-Methoxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine; 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine |
| Routes of administration | Mainly sublingual, buccal, and insufflation |
| Drug class | Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Very low |
| Metabolism | Extensive first-pass metabolism in the liver |
| Onset of action | 15–120 min (0.25–2 hours) |
| Duration of action | Insufflation: 4–6 h Sublingual: 6–10 h Buccal: 6–10 h |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H22INO3 |
| Molar mass | 427.282 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
25I-NBOMe, also known as 2C-I-NBOMe, Cimbi-5, and shortened to "25I", is a psychedelic drug of the phenethylamine, 2C, and NBOMe (25-NB) families. Since 2010, it has circulated in the recreational drug scene, often misrepresented as LSD. It is the most well-known member of the 25-NB family and the earliest member to be encountered as a novel recreational drug.
The carbon-11 labelled version of 25I-NBOMe, [11C]Cimbi-5, was synthesized and validated as a radiotracer for positron emission tomography (PET) in Copenhagen. Being the first 5-HT2A receptor full agonist PET radioligand, [11C]CIMBI-5 shows promise as a more functional marker of these receptors, particularly in their high affinity states.
Street and media nicknames for this drug include "N-Bomb", "Solaris", "Smiles", and "Wizard", although the drug is frequently fraudulently sold as LSD.
Due to its physical effects and risk of overdose, there have been multiple deaths attributed to the drug. Its long-term toxicity is unknown due to lack of existing research.
25I-NBOMe was first described in 2000. It was first encountered as a novel recreational drug in 2010, and by 2012, NBOMes like 25I-NBOMe had surpassed other major psychedelics like LSD and psilocybin-containing mushrooms in popularity, at least for a time. 25I-NBOMe became a controlled substance in the United States in 2013.